She testified before the Senate Democratic Policy Committee Hearing in 2007 about her experience blowing the whistle and the aftermath of her disclosure.
With other whistleblowers, Richardson filed qui tam action against their employer for illegal drug pricing and marketing activities that resulted in increased and costs.